A key federal committee gave its OK for pediatricians to make MedImmune’s FluMist available to patients in the next flu season — a big win for parent company AstraZeneca which saw its flu vaccine’s U.S. sales decimated in the last two flu seasons because of previous negative recommendations.
{iframe}https://www.bizjournals.com/washington/news/2018/02/21/after-back-to-back-busts-medimmune-wins-key.html{/iframe}